Table 1. Efficacy of RL-81 Analogues in Human Kv7 Channel Conductance Studiesa.
compd | X | Y | R1 | R2 | R3 | R4 | R5 | R6 | R7 | Kv7.2/3 EC2x ± SD [μM] | Kv7.3/5 EC2x ± SD [μM] | Kv7.4 EC2x ± SD [μM] | Kv7.4/5 EC2x ± SD [μM] | SI |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FP | CH | CH | F | H | H | Nb | H | H | Et | 2.00 ± 0.69 | 1.58 ± 0.69 | 5.62 ± 1.86 | 3.50 ± 2.68 | 1.8 |
RG | CH | CH | F | H | H | H | H | H | Et | 0.33 ± 0.08 | 0.34 ± 0.04 | ND | ND | ND |
RL-81 | CH | CH | CF3 | H | H | F | H | H | Et | 0.26 ± 0.13 | 0.29 ± 0.06 | 0.10 ± 0.04 | 0.09 ± 0.04 | 0.3 |
RL-73 | CH | CH | H | CF3 | H | F | H | H | Et | 0.14 ± 0.05 | 0.20 ± 0.08 | 0.40 ± 0.13 | 0.66 ± 0.01 | 4.7 |
RL-02 | CH | CH | H | SF5 | H | F | H | H | Et | 0.36 ± 0.25 | 0.21 ± 0.11 | 0.65 ± 0.39 | 0.65 ± 0.28 | 1.8 |
RL-72 | CH | CH | CF3 | H | H | H | F | H | Et | 1.26 ± 0.31 | >10 | 4.65 ± 0.95 | >10 | >7 |
RL-073 | CH | CH | CF3 | H | H | F | CF3 | H | Et | >10 | >10 | >10 | >10 | ND |
RL-32 | CH | CH | CF3 | H | H | F | H | H | i-Pr | 0.16 ± 0.11 | 0.16 ± 0.10 | 0.19 ± 0.10 | 4.98 ± 1.12 | 31 |
RL-56 | CH | CH | CF3 | H | H | F | H | H | c-Pr | 0.11 ± 0.02 | 0.23 ± 0.10 | 0.38 ± 0.30 | 0.28 ± 0.03 | 2.5 |
RL-18 | CF | CH | CF3 | H | H | F | H | H | Et | 0.18 ± 0.11 | 0.34 ± 0.01 | 0.11 ± 0.04 | 0.30 ± 0.26 | 1.7 |
RL-35 | CF | CH | CF3 | H | H | F | H | H | c-Pr | 0.59 ± 0.08 | 0.47 ± 0.01 | 0.21 ± 0.19 | 0.35 ± 0.17 | 0.6 |
RL-36 | CF | CH | CF3 | H | H | F | F | H | c-Pr | 0.93 ± 0.21 | >10 | >10 | >10 | >10 |
RL-46 | CF | CH | CF3 | H | H | F | H | F | c-Pr | 1.47 ± 0.22 | >10 | 0.55 ± 0.14 | >10 | >7 |
RL-50 | CF | CH | CF3 | H | H | F | F | F | c-Pr | >10 | >10 | >10 | >10 | ND |
RL-31 | N | CH | CF3 | H | H | F | H | H | Et | 0.66 ± 0.25 | 0.79 ± 0.26 | 0.85 ± 0.14 | 0.59 ± 0.34 | 0.9 |
RL-68 | N | CH | CF3 | H | H | F | H | H | c-Pr | 0.79 ± 0.03 | 0.72 ± 0.05 | 0.90 ± 0.02 | 0.96 ± 0.05 | 1.2 |
RL-96 | N | CH | CF3 | H | F | F | H | H | c-Pr | 1.39 ± 0.20 | >10 | >10 | >10 | >7 |
RL-01 | N | CH | CF3 | H | F | F | F | H | c-Pr | >10 | >10 | >10 | >10 | ND |
RL-12 | N | CH | CF3 | H | F | F | H | F | c-Pr | 1.00 ± 0.50 | >10 | >10 | >10 | >10 |
RL-23 | N | CCN | CF3 | H | H | F | H | H | Et | 1.60 ± 0.19 | 1.30 ± 0.16 | 2.17 ± 0.37 | 2.33 ± 0.89 | 1.5 |
RL-24 | CH | N | CF3 | H | H | F | H | H | Et | 0.61 ± 0.34 | 0.69 ± 0.35 | 0.95 ± 0.13 | 1.27 ± 0.05 | 2.1 |
RL-67 | CH | N | CF3 | H | H | F | H | H | c-Pr | 0.71 ± 0.23 | 0.69 ± 0.19 | 1.13 ± 0.72 | 1.36 ± 0.70 | 1.9 |
EC2x data were obtained from 10-point concentration curves and 2–5 individual assay determinations, with the exception of FP, for which 6–431 repeats were determined; SD = standard deviation; SI = selectivity index = EC2x(Kv7.4/5)/EC2x(Kv7.2/3); ND = not determined.
FP has a pyridine ring nitrogen at the R4-substituted carbon position.